BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis

被引:221
|
作者
Li, Carol [1 ]
Lee, Kathleen C. [1 ]
Schneider, Eric B. [1 ]
Zeiger, Martha A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Endocrine Surg Sect, Baltimore, MD 21287 USA
来源
基金
美国国家卫生研究院;
关键词
ASPIRATION BIOPSY SPECIMENS; LYMPH-NODE METASTASIS; TALL-CELL VARIANT; BRAF(V600E) MUTATION; HIGH PREVALENCE; GENE MUTATION; HIGH-RISK; CARCINOMA; RECURRENCE; EXPRESSION;
D O I
10.1210/jc.2012-2104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is conflicting literature regarding the association of the BRAF V600E mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC). Nevertheless, some propose that BRAF status be incorporated into the management of patients with PTC, specifically recommendations regarding lymph node dissection. We therefore performed a meta-analysis to examine the relationship between BRAF and clinicopathological features of PTC. Methods: A literature search was performed within PubMed and EMBASE databases using the following Medical Subject Headings (MeSH) and keywords: "braf," "mutation," "thyroid," "neoplasm(s)," "tumor," "cancer," and "carcinoma." Individual study-specific odds ratios and confidence intervals were calculated, as were Mantel-Haenszel pooled odds ratios for the combined studies. Results: Thirty-two studies including 6372 patients were reviewed. BRAF mutation was associated with lymph node metastases (LNM), advanced stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC. There was no association with age or vascular invasion. Only two studies were prospective; nine included consecutive patients, whereas one included randomly selected patients; and only two included patients who had undergone routine central lymph node dissection and were thus evaluable for the presence of LNM. Conclusion: Meta-analysis found that BRAF mutation is associated with LNM, stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC in PTC. However, almost all studies were retrospective and only two of 32 included patients who had undergone routine central lymph node dissection, emphasizing the need for well-designed studies to appropriately examine this association before making important clinical decisions. (J Clin Endocrinol Metab 97: 4559-4570, 2012)
引用
收藏
页码:4559 / 4570
页数:12
相关论文
共 50 条
  • [21] Quantitation and Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma
    Sirohi, D.
    Wang, Y.
    Lindner, J. R.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    LABORATORY INVESTIGATION, 2014, 94 : 159A - 160A
  • [22] DNA methylation profile in papillary thyroid cancer according to BRAF (V600E) mutation
    Beltrami, Caroline Moraes
    dos Reis, Mariana Bisarro
    Barros-Filho, Mateus Camargo
    Marchi, Fabio Albuquerque
    Kuasne, Hellen
    Ambatipudi, Srikant
    Herceg, Zdenko
    Kowalski, Luiz Paulo
    Rogatto, Silvia Regina
    CANCER RESEARCH, 2015, 75
  • [23] Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
    He, Guoping
    Zhao, Baojian
    Zhang, Xu
    Gong, Rixiang
    ONCOLOGY LETTERS, 2014, 7 (02) : 439 - 443
  • [24] Quantitation and Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma
    Sirohi, D.
    Wang, Y.
    Lindner, J. R.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    MODERN PATHOLOGY, 2014, 27 : 159A - 160A
  • [25] Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer
    Shi, Rong-liang
    Qu, Ning
    Liao, Tian
    Wei, Wen-jun
    Lu, Zhong-wu
    Ma, Ben
    Wang, Yu-Long
    Ji, Qing-hai
    TUMOR BIOLOGY, 2016, 37 (06) : 8383 - 8390
  • [26] The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
    Ge, Junshang
    Wang, Jie
    Wang, Hui
    Jiang, Xianjie
    Liao, Qianjin
    Gong, Qian
    Mo, Yongzhen
    Li, Xiaoling
    Li, Guiyuan
    Xiong, Wei
    Zhao, Jin
    Zeng, Zhaoyang
    JOURNAL OF CANCER, 2020, 11 (04): : 932 - 939
  • [27] BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer
    Liu, Zhuoran
    Lv, Tian
    Xie, Cong
    Di, Zhongmin
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2018, 356 (02): : 130 - 134
  • [28] The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
    Ye, Ziheng
    Xia, Xiaotian
    Xu, Peipei
    Liu, Wenfei
    Wang, Shoufei
    Fan, Youben
    Guo, Minggao
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2022, 2022
  • [29] Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma
    Shi, C. L.
    Sun, Y.
    Ding, C.
    Lv, Y. C.
    Qin, H. D.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 7377 - 7385
  • [30] BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
    Silver, Jennifer A.
    Bogatchenko, Mariya
    Pusztaszeri, Marc
    Forest, Veronique-Isabelle
    Hier, Michael P.
    Yang, Ji Wei
    Tamilia, Michael
    Payne, Richard J.
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 50 (01)